Research Analysts’ Weekly Ratings Changes for Ultragenyx Pharmaceutical (RARE)

A number of firms have modified their ratings and price targets on shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) recently:

• 7/18/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
• 7/14/2017 – Ultragenyx Pharmaceutical had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $68.00 price target on the stock.
• 7/11/2017 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
• 6/30/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $111.00 price target on the stock.
• 6/29/2017 – Ultragenyx Pharmaceutical had its “outperform” rating reaffirmed by analysts at Cowen and Company. They wrote, “We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community.””
• 6/22/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
• 6/20/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
• 6/2/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.

Ultragenyx Pharmaceutical Inc. (RARE) traded down 1.31% on Friday, reaching $70.06. The company had a trading volume of 239,349 shares. Ultragenyx Pharmaceutical Inc. has a 12 month low of $51.67 and a 12 month high of $91.35. The firm has a 50-day moving average of $62.37 and a 200-day moving average of $67.89. The stock’s market capitalization is $2.96 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.08. During the same quarter in the prior year, the firm earned ($1.35) EPS. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.04) earnings per share for the current fiscal year.

In other news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the sale, the vice president now directly owns 9,366 shares of the company’s stock, valued at $538,170.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.